CTLA4 and melanoma: The combination of immune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) has demonstrated heightened efficacy in advanced melanoma, albeit with notable side effects.